Drugs that contain Duvelisib

1. List of Copiktra drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8193182 SECURA Substituted isoquinolin-1(2H)-ones, and methods of use thereof
Feb, 2030

(7 years from now)

USRE46621 SECURA Processes for preparing isoquinolinones and solid forms of isoquinolinones
May, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216982 SECURA Certain chemical entities, compositions and methods
Jan, 2029

(5 years from now)

US9840505 SECURA Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof
Jan, 2032

(8 years from now)

US11312718 SECURA Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
Jan, 2032

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 24, 2023
Orphan Drug Exclusivity (ODE) Sep 24, 2025

NCE-1 date: September, 2022

Market Authorisation Date: 24 September, 2018

Treatment: For the treatment of patients with follicular lymphoma (fl); For the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll)


More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic